25-hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18,791 participants.
Brøndum-Jacobsen P, Benn M, Tybjaerg-Hansen A, Nordestgaard BG.
Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Denmark; The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Denmark; The Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Vitamin D has potential antithrombotic effects suggesting that vitamin D analogs could be used as adjunctive antithrombotic agents. However, epidemiological evidence of an association between reduced 25-hydroxyvitamin D concentrations and risk of venous thromboembolism is lacking.
We tested the hypothesis that reduced plasma 25-hydroxyvitamin D concentrations associate with increased risk of venous thromboembolism in the general population.
We prospectively studied 18,791 participants from the Copenhagen City Heart Study and the Copenhagen General Population Study. During up to 30 years of follow-up, 950 participants were diagnosed with venous thromboembolism. Plasma 25-hydroxyvitamin D concentrations were adjusted for seasonal variation.
Cumulative incidence of venous thromboembolism as a function of age increased with decreasing tertiles of seasonally adjusted plasma 25-hydroxyvitamin D (log-rank trend:p= 4×10(-4) ). Comparing participants in the lowest versus the highest tertile of plasma 25-hydroxyvitamin D concentrations, the crude risk estimates in an age and sex adjusted model was a 37% (95% confidence interval: 15%-64%) increased risk of venous thromboembolism. Corresponding risk increases in an age, sex, body mass index, smoking, and cancer adjusted model was 26% (5%-51%), and in a multivariable adjusted model further including physical activity, hormone replacement therapy, menopausal status, oral contraception use, and lipid lowering therapy 28% (6%-53%). Furthermore, corresponding risk increases with attempts to correct for regression dilution bias were 103% (37%-202%), 70%(14%-155%), and 73%(15%-160%) in the three models, respectively.
In these large general population studies, we observed stepwise increasing risk of venous thromboembolism with decreasing tertiles of seasonally adjusted plasma 25-hydroxyvitamin D concentrations.
© 2012 International Society on Thrombosis and Haemostasis.
Download the PDF from VitaminDWiki
- 300,000 IU of vitamin D injection not enough to statistically reduce markers of Venous Thromboembolism – RCT July 2016
suspect that 500,000 IU OR d injections of 300,000 IU, OR 500,000 IU over 3 months would have been enough
- Vitamin D level higher than 30 ng reduces diabetic blood clotting – Nov 2012
- Overview Cardiovascular and vitamin D
- All items in Cardiovascular and Vitamin D
- All items in category Hypertension
- All items in category Strokes and Vitamin D
- Surgical outcomes are better for higher levels of Vitamin D – systematic review May 2015
- 1.5X increased infection, sepsis, and death if in ICU with low vitamin D - Meta-analysis Dec 2014
Higher vitamin D levels associated with fewer vein clots decades later– Jan 2013
- Higher rates of venous thromboembolism for Black-Americans are likely due to lower serum 25-hydroxyvitamin D levelsDr. Grant Nov 2010
- Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. April 2009
- Does vitamin D prevent formation of blood clots? Vitamin D Council blog on this study
- Blood Clot Prevention Is Higher Priority at Hospitals
Wall Street Journal Aug 2015, no mention of vitamin D
6900 visitors, last modified 28 Jan, 2017,This page is in the following categories (# of items in each category)
- All items in category Hypertension